Moran Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Moran Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-644	Closed	-$312K	–	516
2025 Q1	$312K	Sell	644 -29,300	-98%	-$13.7M	0.01%	397
2024 Q4	$12.1M	Buy	29,944 +866	+3%	+$401K	0.38%	90
2024 Q3	$13.5M	Buy	29,078 +459	+2%	+$220K	0.42%	83
2024 Q2	$13.4M	Buy	28,619 +1,274	+5%	+$553K	0.44%	75
2024 Q1	$11.4M	Buy	27,345 +438	+2%	+$185K	0.37%	92
2023 Q4	$10.9M	Buy	26,907 +1,962	+8%	+$725K	0.39%	89
2023 Q3	$8.67M	Buy	24,945 +945	+4%	+$330K	0.34%	107
2023 Q2	$8.45M	Sell	24,000 -445	-2%	-$150K	0.32%	110
2023 Q1	$7.7M	Buy	24,445 +9,015	+58%	+$2.7M	0.29%	118
2022 Q4	$4.46M	Buy	+15,430	New	+$4.7M	0.17%	164

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Moran Wealth Management's VRTX Position: Q2 2025 in Review

Moran Wealth Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 644 shares — an estimated $312K sold.

Moran Wealth Management first reported a position in VRTX in Q4 2022 and held it in 10 quarters. The position peaked at $13.5M in Q3 2024. 1,563 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

Moran Wealth Management reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Moran Wealth Management sold 644 Vertex Pharmaceuticals shares in Q2 2025, an estimated $312K.
Moran Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2022 and held it in 10 quarters.
Moran Wealth Management's Vertex Pharmaceuticals position peaked at $13.5M in Q3 2024.
1,563 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on Moran Wealth Management's 13F filing for Q2 2025, filed 28 Jul 2025.